Trials / Unknown
UnknownNCT02039791
Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Cervical Cancer
Phase II Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Cervical Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Biotech Pharmaceutical Co., Ltd. · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Nimotuzumab is a humanized monoclonal antibody against epidermal growth factor receptor (EGFR). Clinical trials are ongoing globally to evaluate Nimotuzumab in different indications. Nimotuzumab has been approved to treat squamous cell carcinoma of head and neck (SCCHN), glioma and nasopharyngeal carcinoma in different countries. The clinical phaseⅡtrial is designed to assess the resection rate and pathological complete response of nimotuzumab plus carboplatin and paclitaxel in patients with cervical cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Nimotuzumab | 200mg/w,weekly, 6 weeks |
| DRUG | Carboplatin | AUC 6, d1，1 cycle/21d, 2 cycles |
| DRUG | Paclitaxel | 175 mg/m2, d1 1 cycle/21d, 2 cycles. |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2016-06-01
- Completion
- 2016-08-01
- First posted
- 2014-01-20
- Last updated
- 2015-08-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02039791. Inclusion in this directory is not an endorsement.